Results for “Durata Therapeutics”

Inc Therapeutics 2005 15.6 7.1 - 7.1 0.46 0.46 -11.5%

Inc. Therapeutics 2006 6.2 - 6.8 6.8 - 1.11 1.5%

Inc. Therapeutics 2007 36.9 - 186.9 186.9 - 5.06 39.9%

Inc. Therapeutics 2007 23.7 - 61.8 61.8 - 2.60 27.5%

Inc. Therapeutics 2005 19.6 - 7.2 Pd. - 0.37 -14.6%

Inc. Therapeutics 2006 19.4 - 19.6 19.6 - 1.01 0.2%

Inc. Therapeutics 1999 5.1 25.6 - 25.6 5.01 5.01 293.2%

Inc. Therapeutics 1998 19.9 41 - 41 0.20 0.20 -30.3%

Inc. Therapeutics 2000 15.0 1.6 - 1.6 0.11 0.11 -35.3%

ACKRELL CAPITAL CHAPTER VII Capital Markets for Cannabis Companies Over The Counter (Market Value Greater than $25 million) Enterprise Value (EV) LTM Revenue LTM LTM EV Multiples EBITDA Revenue EBITDA ($U.S. millions, except stock price) Stock % Below Price 52-Week Mark...

IV. OPPORTUNITY IN THE HEALTHCARE SECTOR The Fund Managers believe a number of macro market factors have aligned to create attractive and lasting conditions for NLV-III’s targeted investment strategy in healthcare technology. Each of these market factors individually would have...

Manic-Depressive Illness. Fred K. Goodwin and Kay R. Jamison, Oxford Univ. Press, N.Y. 1990. The Pharmacological Basis of Therapeutics. Louis S. Goodman and Alfred Gilman, MacMillan, N.Y. 1975. Statistical Mechanics of Phase Transitions. J.M. Yeomans, Clarendon Press, Oxford. 1...

BIOLOGY MEDICINE An Unlikely Cure Signals New Hope for Cancer How “exceptionalresponders’ ‘arerevolutionizing treatment for the deadly desease BY KAT MCGOWAN UST LIKE EVERY NEW drug the oncologists at Memorial Sloan-Kettering Cancer Center test- ed against bladder cancer i...

Inc. OTCPK:THCT 0.34 60.6% 39.7 39.7 0.0 0.0 NM NM

There is no question that the shift to value-based reimbursement models will have a major impact on the economics of healthcare. Payers will be looking for ways to significantly reduce costs in all areas where a range of viable lower cost solutions are available, and will force p...